Sarepta Therapeutics, Inc. Stock

$17.11

0.70% day before yesterday

Nasdaq, Jun 27, 10:10 pm CET

ISIN

US8036071004

Symbol

SRPT

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Sarepta Therapeutics, Inc. Stock price

$17.11

-145.60 89.48% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.12 0.70%

ISIN

US8036071004

Symbol

SRPT

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$1.7b

Enterprise Value

$2.3b

Net debt

$615.5m

Cash

$522.8m

Shares outstanding

98.3m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.75 | 0.70

EV/Sales

1.03 | 0.95

EV/FCF

negative

P/B

1.47

Financial Health

Equity Ratio

38.55%

Return on Equity

15.40%

ROCE

-4.10%

ROIC

-7.01%

Debt/Equity

1.00

Financials (TTM | estimate)

Revenue

$2.2b | $2.4b

EBITDA

$-114.8m | $-89.8m

EBIT

$-117.2m

Net Income

$-248.4m | $-252.4m

Free Cash Flow

$-697.6m

Growth (TTM | estimate)

Revenue

59.16% | 26.87%

EBITDA

-23.70% | -140.72%

EBIT

-23.68%

Net Income

-1,563.70% | -207.29%

Free Cash Flow

-6.68%

Margin (TTM | estimate)

Gross

81.82%

EBITDA

-5.14% | -3.72%

EBIT

-5.25%

Net

-11.12% | -10.46%

Free Cash Flow

-31.23%

EPS

$-2.55

FCF per Share

$-7.10

Short interest

11.79%

Employees

1.37k

Rev per Employee

$1.39m

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Sarepta Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

32 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

26x Buy

81%

6x Hold

19%

More details on Analyst Estimates Including Price Targets

32 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

Buy

81%

Hold

19%

Analyst Estimates with Stock Price Targets

Financial data from Sarepta Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2,233 2,233	59% 59% 100%
- Direct Costs	406 406	145% 145% 18%
Gross Profit	1,827 1,827	48% 48% 82%
- Selling and Administrative Expenses	565 565	13% 13% 25%
- Research and Development Expense	1,378 1,378	66% 66% 62%
EBITDA	-115 -115	24% 24% -5%
- Depreciation and Amortization	2.41 2.41	23% 23% 0%
EBIT (Operating Income) EBIT	-117 -117	24% 24% -5%
Net Profit	-248 -248	1,564% 1,564% -11%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sarepta Therapeutics, Inc. Stock News

Neutral

PRNewsWire

●

one day ago

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , June 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

Neutral

Business Wire

●

2 days ago

Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”). Sarepta is a commercial-stage biopharmaceutical company. For more information, subm...

Neutral

GlobeNewsWire

●

2 days ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT)

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) securities between June 22, 2023 and June 24,...

More Sarepta Therapeutics, Inc. News

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Douglas Ingram
Employees	1,372
Founded	1980
Website	www.sarepta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now